Papers/PMID:41565787
Evaluating the antioxidant and anti-inflammatory effect of melatonin in pediatric hemodialysis patients: a randomized, placebo-controlled trial.
Scientific reports2026The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
melatonin — no detected effect on malondialdehyde (circulating)
LikelyGrade B, Likely. Human evidence with one recorded weakness, or capped at B by its design or by unread numbers.FindingNull result“Also, the MLT group demonstrated marginal reduction in MDA compared to placebo group (F = 3.046, p = 0.092, partial η2 = 0.095), revealing a trend towards decreased oxidative stress that did not reach statistical significance.”
Quoted verbatim from Evaluating the antioxidant and anti-inflammatory effect of melatonin in pediatric hemodialysis patients: a randomized, placebo-controlled trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- 5 mg oral melatonin once daily 1 h before bedtime for 12 weeks
- Population
- children on chronic haemodialysis; primary endpoint, ANCOVA adjusted for baseline MDA and antihypertensive use; serum MDA by ELISA
Evaluating the antioxidant and anti-inflammatory effect of melatonin in pediatric hemodialysis patients: a randomized, placebo-controlled trial.2026PMID:41565787Permalink